Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12–49.
Cai R, Zhao F, Zhou H, Wang Z, Lin D, Huang L, et al. A tumor-associated autoantibody panel for the detection of non-small cell lung cancer. Front Oncol. 2022;12:1056572.
Google Scholar
Ramos-Ramirez M, Caballe-Perez E, Lucio-Lozada J, Romero-Nunez E, Castillo-Ruiz C, Dorantes-Sanchez L, et al. Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy. Cancer Metastasis Rev. 2025;44:30.
Google Scholar
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer J Clin. 2022;72:7–33.
Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022;8:CD013829.
Google Scholar
Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction – evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18:135–51.
Google Scholar
Guo L, Yu Y, Yang F, Gao W, Wang Y, Xiao Y, et al. Accuracy of baseline low-dose computed tomography lung cancer screening: a systematic review and meta-analysis. Chin Med J (Engl). 2023;136:1047–56.
Google Scholar
Baldwin RW. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer. 1966;1:257–64.
Google Scholar
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64.
Google Scholar
Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535–44.
Google Scholar
Jansen K, Kornfeld L, Lennartz M, Dwertmann Rico S, Kind S, Reiswich V, et al. Carcinoembryonic antigen expression in human tumors: a tissue microarray study on 13,725 tumors. Cancers (Basel). 16.2024.
Wellenstein MD, de Visser KE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 2018;48:399–416.
Google Scholar
Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–40.
Google Scholar
Zhuang L, Huang C, Ning Z, Yang L, Zou W, Wang P, et al. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Int J Cancer. 2023;152:1013–24.
Google Scholar
Zhang X, Liu M, Zhang X, Wang Y, Dai L. Autoantibodies to tumor-associated antigens in lung cancer diagnosis. Adv Clin Chem. 2021;103:1–45.
Google Scholar
Zhou ZR, Wu MS, Yang Z, Wu Y, Guo W, Li DW, et al. Synthetic transmembrane DNA receptors enable engineered sensing and actuation. Nat Commun. 2025;16:1464.
Google Scholar
Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak S, Collins CAF, et al. Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. J Biol Chem. 2017;292:21180–92.
Google Scholar
Wee P, Wang Z Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 9.2017.
Jiang D, Zhang X, Liu M, Wang Y, Wang T, Pei L, et al. Discovering panel of autoantibodies for early detection of lung cancer based on focused protein array. Front Immunol. 2021;12:658922.
Google Scholar
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58.
Google Scholar
Li Y, Wang L, Chen F, Liao R, Li J, Cao X, et al. Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma. Front Immunol. 2025;16.
Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. Int J Biol Macromol. 2022;202:539–57.
Google Scholar
Dandel M, Wallukat G, Potapov E, Hetzer R. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology. 2012;217:511–20.
Google Scholar
Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell. 2023;186:5084–97 e18.
Google Scholar
Rogers MA, Fantauzzo KA. The emerging complexity of PDGFRs: activation, internalization and signal attenuation. Biochem Soc Trans. 2020;48:1167–76.
Google Scholar
Bastola S, Pavlyukov MS, Sharma N, Ghochani Y, Nakano MA, Muthukrishnan SD, et al. Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma. Nat Commun. 2025;16:471.
Google Scholar
Zhao R, Lian W, Xu Q. Sex hormones and immune regulation in ovarian cancer. Discov Oncol. 2024;15:849.
Google Scholar
Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, et al. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer. 2006;13:113–34.
Google Scholar
Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol. 2009;305:12–21.
Google Scholar
Dubey S, Siegfried JM, Traynor AM. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol. 2006;7:416–24.
Google Scholar
Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62:2141–50.
Google Scholar
Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, et al. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000;45:122–8.
Google Scholar
Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011;13:R25.
Google Scholar
Zhang H, Tian L, Wang X, Shi X. The relationship between thyroid peroxidase antibody and differentiated thyroid cancer: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1349041.
Google Scholar
Lai CL, Tsai CM, Tsai TT, Kuo BI, Chang KT, Fu HT, et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res. 1998;4:3025–30.
Google Scholar
Pan J, Song G, Chen D, Li Y, Liu S, Hu S, et al. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Mol Cell Proteom. 2017;16:2069–78.
Google Scholar
Ren S, Zhang S, Jiang T, He Y, Ma Z, Cai H, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology. 2018;7:e1384108.
Google Scholar
Chen P, Lu W, Chen T. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer. J Clin Lab Anal. 2021;35:e24020.
Google Scholar
Ye Y, Huang Y, Pan J. Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer. Front Immunol. 2025;16:1538071.
Google Scholar
Dai Y, Aizenbud L, Qin K, Austin M, Jaycox JR, Cunningham J, et al. Humoral determinants of checkpoint immunotherapy. Nature. 2025;644:527–36.
Google Scholar
